Central Trust Company’s Haemonetics HAE Stock Holding History

Central Trust Company’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-60	Closed	-$5K	–	1079
2020 Q2	$5K	Buy	+60	New	+$6.06K	﹤0.01%	922

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Central Trust Company's HAE Position: Q3 2020 in Review

Central Trust Company sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 60 shares — an estimated $5K sold.

Central Trust Company first reported a position in HAE in Q2 2020 and held it in 1 quarter. The position peaked at $5K in Q2 2020. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

Central Trust Company reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
Central Trust Company sold 60 Haemonetics shares in Q3 2020, an estimated $5K.
Central Trust Company first reported a position in Haemonetics in Q2 2020 and held it in 1 quarter.
Central Trust Company's Haemonetics position peaked at $5K in Q2 2020.
268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Central Trust Company's 13F filing for Q3 2020, filed 22 Oct 2020.